BMY Stock Recent News
BMY LATEST HEADLINES
Bristol Myers Squibb aims to expand its research and development presence in India and expects its newly inaugurated Hyderabad facility to become its largest unit outside the U.S. by 2025, CEO Christopher Boerner said on Tuesday.
BXMT, BMY and CWEN have been added to the Zacks Rank #5 (Strong Sell) List on February 26, 2023.
Bristol Myers (BMY) announces FDA's acceptance of the sNDA seeking approval for the Krazati/Erbitux combo therapy to treat CRC patients. A final decision is expected on Jun 21, 2024.
Bristol Myers Squibb BMY (NYSE: BMY) reported its Q4 results earlier this month, with revenues and earnings beating the street estimates. The company reported revenue of $11.5 billion and adjusted earnings of $1.70 per share compared to the consensus estimates of $11.2 billion in sales and $1.53 profit per share.
Picking the best stocks for beginning investors is crucial as they enter the world of long-term investing. With a myriad of options available, it's essential to focus on stocks that offer growth potential and stability.
Pfizer and Bristol Myers Squibb have delivered poor financial results of late. Some investors might worry about the future of their dividend programs.
Every month we look at companies that are delivering not only a solid dividend yield but also showing a trend of growing dividends. Companies that can consistently deliver dividend growth due to rising earnings can generate long-term wealth. February 2024's dividend screening article gives us a look at some familiar names but two new names we haven't discussed before.
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
ACLS, BMY and CHX have been added to the Zacks Rank #5 (Strong Sell) List on February 12, 2023.
Drugmakers grilled on the cost of prescription drugs on Capitol Hill Thursday sought to deflect the criticism onto drug-market middlemen who they said are pushing list prices for medications higher.